trending Market Intelligence /marketintelligence/en/news-insights/trending/Z6KEBnH6M9hkX7JPaw3tbQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

RJ Biotech fiscal Q3 profit climbs 84.6% YOY


What’s the Bottom Line: Credit Impact of COVID-19 on US Municipals


Banking Essentials Newsletter - February Edition, Part 2


Episode 3: Transformation of Customer Experience in 2020


Episode 2: Origins of 451 Research - Part 2

RJ Biotech fiscal Q3 profit climbs 84.6% YOY

RJ Biotech Ltd. said its normalized net income for the fiscal third quarter ended Dec. 31, 2015, amounted to 76 Indian paise per share, an increase of 84.8% from 41 paise per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 7.2 million rupees, an increase of 84.6% from 3.9 million rupees in the prior-year period.

The normalized profit margin increased to 11.6% from 5.2% in the year-earlier period.

Total revenue decreased 16.7% on an annual basis to 62.1 million rupees from 74.5 million rupees, and total operating expenses fell 28.9% from the prior-year period to 42.3 million rupees from 59.5 million rupees.

Reported net income increased 84.6% year over year to 11.5 million rupees, or 1.22 rupees per share, from 6.3 million rupees, or 66 paise per share.

As of Feb. 2, US$1 was equivalent to 67.97 Indian rupees.